From MIGS integration to remote monitoring and next-generation therapeutics, glaucoma specialists explore how new approaches ...
Two sustained-release procedural pharmaceuticals or drug-delivery options are available in the US: the bimatoprost ...
Through 24 months, scleral bio-reinforced cyclodialysis combined with cataract surgery lowered IOP by enhancing uveoscleral ...
A new population-based study published in the journal of Advances in Therapy revealed that individuals diagnosed with ...
Please provide your email address to receive an email when new articles are posted on . Data supported the practice of using a size V stimulus when sensitivity is too low with size III. Size V had ...
Benefit rules shift with quiet consequences for households already stretched. Fresh guidance will shape reviews, payments and ...
Q3 2025 Earnings Call October 29, 2025 4:30 PM EDTCompany ParticipantsChristopher Lewis - Vice President of Investor ...
The Manila Times on MSN
South Sudan's blind football team dreams of Paralympic glory
Yona Sabri Ellon cannot see the ball at his feet, but he can hear it.Blind football uses a bell in the ball to direct players ...
The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
Among them, Lucentis® is the first anti-vascular endothelial growth factor (VEGF) drug approved for ophthalmic use in China, and has accumulated mature clinical application experience, providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback